GlassScriptPhysician profile
Andrew D Hirsch
NPI 1932147147
$15,060.28
in general payments reported to CMS, 2019-2025
50 companies · $2,421 in 2025
The $2,421 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,188 · 2020: $1,354 · 2021: $1,403 · 2022: $1,707 · 2023: $2,882 · 2024: $3,104 · 2025: $2,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,407.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,717.39 | 2019-2025 | |
| Lilly USA, LLC | $1,883.51 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,601.27 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,100.77 | 2019-2025 | |
| Novo Nordisk INC | $986.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $904.00 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $747.43 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $652.18 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $424.94 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $403.58 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $323.98 | 2020-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $311.79 | 2019-2025 | |
| Amarin Pharma, INC. | $303.60 | 2019-2023 | |
| Abbott Laboratories | $280.65 | 2023-2025 | Freestyle Libre |
| Phathom Pharmaceuticals, INC. | $224.90 | 2024-2025 | Voquezna |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Hirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.